885609-84-7

Basic information

• Product Name: PropanaMide, N-(2-broMo-5-fluorophenyl)-2,2-diMethyl-
• Synonyms: PropanaMide, N-(2-broMo-5-fluorophenyl)-2,2-diMethyl-;N-(2-broMo-5-fluorophenyl)pivalaMide;N-(2-BroMo-5-fluoro-phenyl)-2,2-diMethyl-propionaMide
• CAS NO: 885609-84-7
• Molecular Formula: C₁₁H₁₃BrFNO
• Molecular Weight: 274.1294232
• Mol File: 885609-84-7.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: PropanaMide, N-(2-broMo-5-fluorophenyl)-2,2-diMethyl-(CAS DataBase Reference)
• NIST Chemistry Reference: PropanaMide, N-(2-broMo-5-fluorophenyl)-2,2-diMethyl-(885609-84-7)
• EPA Substance Registry System: PropanaMide, N-(2-broMo-5-fluorophenyl)-2,2-diMethyl-(885609-84-7)

Safety Data

• Hazardous Substances Data: 885609-84-7(Hazardous Substances Data)

Usage

General Description

PropanaMide, N-(2-broMo-5-fluorophenyl)-2,2-diMethyl- is a chemical compound with the molecular formula C13H16BrFN2O. It is a derivative of propanamide, containing a bromine and fluorine-substituted phenyl group and two methyl groups attached to the central carbon atom. PropanaMide, N-(2-broMo-5-fluorophenyl)-2,2-diMethyl- has potential uses in pharmaceutical and agricultural applications, particularly as an intermediate in the synthesis of other organic compounds. Its specific properties and potential uses would depend on its purity and stability, as well as its interactions with other chemicals and biological systems. Further research and testing would be needed to fully understand its potential benefits and risks in various applications.

Upstream product

• 1003-99-2 2-bromo-5-fluoroaniline 
• 3282-30-2 pivaloyl chloride 

Downstream Products

• 1372548-08-7 3-bromo-2-fluoro-6-iodo-5-(pyridin-2-yl)aniline 
• 1372548-06-5 2-(5-bromo-4-fluoro-2-iodo-3-nitrophenyl)pyridine 
• 1372548-10-1 N-(5-bromo-4-fluoro-7-(pyridin-2-yl)benzothiazol-2-yl)benzamide 
• 1202805-96-6 4-bromo-3-fluoro-6-(pyridin-2-yl)-2-nitroaniline 
• 1202805-95-5 N-[4-bromo-3-fluoro-6-(pyridin-2-yl)-2-nitrophenyl]-2,2-dimethylpropanamide 
• 1202805-94-4 N-[4-bromo-5-fluoro-2-(pyridin-2-yl)phenyl]-2,2-dimethylpropanamide 
• 1202805-93-3 N-[5-fluoro-2-(pyridin-2-yl)phenyl]-2,2-dimethylpropanamide 
• 1202805-45-5 N-[5-fluoro-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-2,2-dimethylpropanamide 

Relevant articles and documents

Palladium-catalyzed C(sp3)-H activation: A facile method for the synthesis of 3,4-dihydroquinolinone derivatives

3,4-Dihydroquinolinones were synthesized by the palladium-catalyzed, oxidative-addition-initiated activation and arylation of inert C(sp 3)-H bonds. Pd(OAc)2 and P(o-tol)3 were used as the catalyst and ligand, respectively, to improve the efficiency of the reaction. A further advantage of this reaction is that it could be performed in air. A relatively rare seven-membered palladacycle was proposed as a key intermediate of the catalytic cycle.

BENZOTHIAZOLES AND AZA-ANALOGUES THEREOF USE AS ANTIBACTERIAL AGENTS

The present invention provides Gyrase B and/or Topoisomerase IV par E inhibitors, which can be used as antibacterial agents. Compounds disclosed herein can be used for treating or preventing conditions caused by or contributed by gram positive, gram negative and anaerobic bacteria, more particularly against, for example, Staphylococci, Streptococci, Enterococci, Haemophilus, Pseudomonas spp., Acenetobacter spp., Moraxalla spp., Chlamydia spp., Mycoplasma spp., Legionella spp., Ktycobacterium spp., Helicobacter, Clostridium spp., Bacteroides spp., Coryne bacterium, Bacillus spp., Enterobactericeae,' (E.coli, Klebsiella spp., Proteus spp.,etc. ) or any combination thereof Also provided, are processes for preparing compounds disclosed herein, pharmaceutical compositions containing compounds disclosed herein, and methods of treating bacterial infections. (Formula)

Constrained compounds as CGRP-receptor antagonists

The invention encompasses constrained bicyclic and tricyclic CGRP-receptor antagonists, methods for identifying them, pharmaceutical compositions comprising them, and methods for their use in therapy for treatment of migraine and other headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.